Literature DB >> 7475053

Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia.

S A Rees1, M J Curtis.   

Abstract

We tested the hypothesis that blockade of the ATP-sensitive K+ channel (IK(ATP)) is an antiarrhythmic mechanism in acute myocardial ischaemia, using an opener of the channel (10 microM RP 49356, RP) and a blocker of the channel (10 microM glibenclamide, GL) and a combination of the two drugs (GL+RP, 10 microM each) in a randomised blinded study. Isolated rat hearts (n = 8 per group) were subjected to 30-min left regional ischaemia. GL and GL+RP widened QT interval after 10-min ischaemia (197 +/- 39 and 203 +/- 20 ms, respectively vs. 154 +/- 12 ms in controls), whereas RP significantly shortened QT interval (123 +/- 6 ms). GL and GL+RP decreased coronary flow (p < 0.05). RP caused slight increase in flow during ischaemia. These effects are all consistent with modulation of vascular and cardiac IK(ATP). RP alone had no effect on ischaemia-induced arrhythmias. Neither did GL have any effect on the incidence of ventricular fibrillation (VF: 88 vs. 100% in controls). However, GL reduced the incidence of sustained VF (VF lasting continuously for > 2 min) to 14% vs. 88% in controls (p < 0.05). Therefore, GL had defibrillatory activity. Surprisingly, in view of these findings, the GL+RP combination significantly reduced the incidence of VF to 25% (from 100% in control hearts, p < 0.05) i.e., had an antifibrillatory effect. So, two agents that produce pharmacological effects attributable to block and opening of IK(ATP) when administered singly had no effects on the incidence of ischaemia-induced VF.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475053     DOI: 10.1097/00005344-199508000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes.

Authors:  P Schaffer; B Pelzmann; E Bernhart; P Lang; H Mächler; B Rigler; B Koidl
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 2.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  K+ channel opening: a new drug principle in cardiovascular medicine.

Authors:  I Gussak; F Bjerregaard
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

4.  The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 5.  Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

Authors:  Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo
Journal:  Trends Endocrinol Metab       Date:  2017-05-22       Impact factor: 12.015

6.  Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

Authors:  Ellen Andrag; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

Authors:  Kathryn E Baker; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.